Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 17, 2009 Brian Orelli	Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount
The Motley Fool September 15, 2011 Brian Orelli	Stop Worrying About Pfizer's Breakup Sometimes you just have to trust management.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
The Motley Fool July 8, 2011 Brian Orelli	Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block.
The Motley Fool October 27, 2009 Brian Orelli	Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions?
The Motley Fool February 17, 2011 Alex Dumortier	Seize Your Chance to Beat the Pros! An area of genuine opportunity for the small investor. Spinoffs remain an underappreciated area in which the individual investor actually gains an edge over institutions.
The Motley Fool January 28, 2009 Brian Orelli	A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer.
The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
The Motley Fool September 2, 2009 Brian Orelli	Should You Buy This Spinoff? Cardinal Health kicks its baby out of the nest.
The Motley Fool September 30, 2009 Brian Orelli	Bigger Size, Lower Returns History is not on Merck and Schering's side.
The Motley Fool December 17, 2009 Brian Orelli	This Acquisition Hears, Smells, and Tastes Soooo Good Johnson & Johnson picks up an ear, nose, and throat medical device maker.
The Motley Fool June 30, 2010 Brian Orelli	Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources.
The Motley Fool July 8, 2010 Brian Orelli	Surprise Us in a Good Way, Merck Keeping up productivity during plant closures won't be easy.
The Motley Fool February 24, 2009 Brian Orelli	Medtronic Hearts Acquisitions Medical device maker Medtronic pays a little over $1 billion for two acquisitions in one day.
The Motley Fool February 9, 2009 Robert Steyer	Just Say No to Drug Company Mergers There are some reasons to make a big-pharma deal. But there are as many, if not more, reasons to let these companies pursue smaller deals and collaborations rather than become just another part of a hyphenated corporate name.
The Motley Fool May 12, 2009 Brian Orelli	Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners.
The Motley Fool November 4, 2009 Brian Orelli	An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem.
The Motley Fool November 25, 2009 Brian Orelli	A Schizophrenic Move by Merck? Issue $29 billion in shares, buy back $3 billion. Say what? Merck increased its share count by almost 45% to pay for the acquisition of Schering-Plough. Now it's planning to buy some of that stock back.
The Motley Fool January 17, 2012 Brian Orelli	Pharma Focus Is Good For Your Portfolio Build your own portfolio.
The Motley Fool June 26, 2009 Brian Orelli	Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss.
The Motley Fool October 23, 2009 Brian Orelli	I Don't Need No Massive Merger Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool November 9, 2009 Brian Orelli	Guidant: The Gift That Keeps on Giving And not in the good way. Last year, Boston Scientific took a whopping $2.7 billion goodwill writedown because it had to downgrade the value of what it got in acquiring Guidant.
The Motley Fool April 29, 2009 Brian Orelli	Parachutes, Cliffs, and Softer Landings Bristol-Myers Squibb faces a major patent cliff in a few years, and it's doing everything it can to make the fall as painless as possible. Early indications from yesterday's first-quarter earnings report look promising.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool January 17, 2006 Stephen D. Simpson	High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this.
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool June 4, 2009 Brian Orelli	MegaMergers Going to the Dogs It looks like Merck isn't sure it'll be able to get its acquisition of Schering-Plough past regulators without doing a little trimming.
The Motley Fool April 15, 2011 Brian Orelli	Dark Clouds Lift Over Pharma Dispute The case of who bought whom in the Merck -Schering-Plough deal has ended in a draw.
The Motley Fool May 25, 2004 Ben McClure	In a Spin Spinoffs can be great investments. Just don't fall for a spin job. Sure, spinoffs are good for investment bankers and their client companies. But are they any good for shareholders, or are they just a convenient way for companies to off-load junk?
The Motley Fool January 27, 2004 Jeff Hwang	Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings.
The Motley Fool August 12, 2011 David Williamson	What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter?
The Motley Fool June 13, 2006 Jim Mueller	Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note.
The Motley Fool May 21, 2009 Brian Orelli	Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose.
The Motley Fool February 19, 2009 Robert Steyer	IPO Food for Thought The bosses at Pfizer should be interested in the recent Mead Johnson IPO so as to place a value on Wyeth's nutrition business.
The Motley Fool January 12, 2012 Brian Orelli	What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see.
The Motley Fool February 11, 2009 Rick Aristotle Munarriz	This IPO Is Hot, Baby Baby formula maker Mead Johnson goes public, snatched from the womb of parent Bristol-Myers Squibb and displayed to the cheering masses.
The Motley Fool July 29, 2011 Brian Orelli	Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last?
The Motley Fool September 17, 2008 Brian Orelli	IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business.
The Motley Fool July 24, 2009 Brian Orelli	Bristol-Myers: Eat or Be Eaten Bristol-Myers Squibb, the oft-rumored acquisition target of partner sanofi-aventis, is doing a little acquiring of its own, which might settle down the rumor mill.
The Motley Fool March 2, 2010 Brian Orelli	Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off.
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.
Entrepreneur November 2001 Mark Henricks	Fallen Branches When subsidiaries fail on their own, how do you bring them back into the fold?
The Motley Fool October 23, 2008 Brian Orelli	Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter.
The Motley Fool January 14, 2010 Brian Orelli	JPMorgan Challenge: Do You "Heart" This Company? A look at Edwards Lifesciences and its heart valves.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool June 29, 2006 Jim Mueller	Guidant, Devices, and Recalls, Oh My! To repair its acquisition's good name, Boston Scientific must quickly fix Guidant's problems. One analyst sees annual growth for Guidant's devices in the 10% to 15% range. No one knows how accurate that will prove to be, but it certainly provides hope for the troubled acquisition.
The Motley Fool February 1, 2010 Brian Orelli	Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost.
The Motley Fool September 30, 2008 Brian Orelli	Cardinal Health Clips Its Wings Does it make sense for the drug wholesaler to spin off its medical equipment business?